United Therapeutics Corporation UTHR shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for ...

In finding that Sandoz and RareGen failed to demonstrate they were likely to prevail in the litigation, the Court noted that Sandoz and RareGen "produced no evidence UTC's purchase of [the cartridges ...

Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years. Remunity ® Pump for Remodulin ® (treprostinil; ...

United Therapeutics Corporation’s UTHR revealed though an 8-K filing that it was informed (Mar 15, 2016) by its partner Medtronic plc MDT that the FDA had issued a response letter to Medtronic’s ...

RESEARCH TRIANGLE PARK, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Treprostinil Injection, a generic form of ...

Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...

Liquidia and Sandoz are poised to introduce a generic, subcutaneous version of United Therapeutics’ Remodulin to the U.S. market. Details of the planned launch emerged after Liquidia’s partner secured ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...